NCT01804686 2026-04-13
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
Clinical Trials
7 trialsNCT02159755 2026-04-13
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03478514 2026-04-09
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT02682641 2026-03-27
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Active not recruiting
NCT02446236 2026-03-24
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Hackensack Meridian Health
Phase 1 Active not recruiting
NCT01479842 2026-03-23
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03282396 2026-03-20
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting